Abstract
The 5-HT 6 receptor subtype is predominantly expressed in the central nervous system, and preclinical evidence suggests that it plays a critical role in the regulation of molecular pathways underlying cognitive function. Patients with schizophrenia show cognitive impairment as a fundamental symptom, and it is proposed that the procognitive properties of some antipsychotics such as olanzapine and clozapine would be, in part, due to the central blockade of 5-HT 6 receptors. In this study, we characterized the brain 5-HT 6 receptor occupancy of olanzapine, clozapine and chlorpromazine in relation to their pharmacokinetic profiles using in vivo [ 3H]GSK215083 binding assay in rat brain. Oral administration of olanzapine (3 mg/kg), clozapine (30 mg/kg) and chlorpromazine (30 mg/kg) produced significant 5-HT 6 receptor occupancy in the brain, inhibiting radioligand binding by 88, 97 and 81%, respectively. The blood concentrations required to achieve significant occupancy were clinically achievable (9.6, 26.9 and 98.6 nM for olanzapine, clozapine and chlorpromazine, respectively). This data provides preclinical evidence to support the hypothesis that brain 5-HT 6 antagonism contributes to the procognitive properties of antipsychotic drugs such as olanzapine and clozapine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
